396 related articles for article (PubMed ID: 20606035)
21. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
22. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.
Masuda M; Shimomura M; Kobayashi K; Kojima S; Nakatsura T
Oncol Rep; 2011 Nov; 26(5):1273-9. PubMed ID: 21725613
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
Leung E; Kim JE; Rewcastle GW; Finlay GJ; Baguley BC
Cancer Biol Ther; 2011 Jun; 11(11):938-46. PubMed ID: 21464613
[TBL] [Abstract][Full Text] [Related]
24. Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.
Marone R; Erhart D; Mertz AC; Bohnacker T; Schnell C; Cmiljanovic V; Stauffer F; Garcia-Echeverria C; Giese B; Maira SM; Wymann MP
Mol Cancer Res; 2009 Apr; 7(4):601-13. PubMed ID: 19372588
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
[TBL] [Abstract][Full Text] [Related]
26. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Awasthi N; Yen PL; Schwarz MA; Schwarz RE
J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
[TBL] [Abstract][Full Text] [Related]
28. Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.
Rosich L; Montraveta A; Xargay-Torrent S; López-Guerra M; Roldán J; Aymerich M; Salaverria I; Beà S; Campo E; Pérez-Galán P; Roué G; Colomer D
Oncotarget; 2014 Aug; 5(16):6788-800. PubMed ID: 25216518
[TBL] [Abstract][Full Text] [Related]
29. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X
Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698
[TBL] [Abstract][Full Text] [Related]
30. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis.
Pollizzi K; Malinowska-Kolodziej I; Stumm M; Lane H; Kwiatkowski D
Mol Cancer; 2009 Jun; 8():38. PubMed ID: 19527517
[TBL] [Abstract][Full Text] [Related]
31. RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.
Earwaker P; Anderson C; Willenbrock F; Harris AL; Protheroe AS; Macaulay VM
PLoS One; 2018; 13(2):e0191890. PubMed ID: 29389967
[TBL] [Abstract][Full Text] [Related]
32. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
Breuleux M; Klopfenstein M; Stephan C; Doughty CA; Barys L; Maira SM; Kwiatkowski D; Lane HA
Mol Cancer Ther; 2009 Apr; 8(4):742-53. PubMed ID: 19372546
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.
Blaser B; Waselle L; Dormond-Meuwly A; Dufour M; Roulin D; Demartines N; Dormond O
BMC Cancer; 2012 Mar; 12():86. PubMed ID: 22401294
[TBL] [Abstract][Full Text] [Related]
34. Levels of p27 sensitize to dual PI3K/mTOR inhibition.
Lee M; Theodoropoulou M; Graw J; Roncaroli F; Zatelli MC; Pellegata NS
Mol Cancer Ther; 2011 Aug; 10(8):1450-9. PubMed ID: 21646547
[TBL] [Abstract][Full Text] [Related]
35. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability.
Seo BR; Min KJ; Cho IJ; Kim SC; Kwon TK
PLoS One; 2014; 9(4):e95588. PubMed ID: 24743574
[TBL] [Abstract][Full Text] [Related]
36. NVP-BEZ235 Inhibits Renal Cell Carcinoma by Targeting TAK1 and PI3K/Akt/mTOR Pathways.
Li B; Zhang X; Ren Q; Gao L; Tian J
Front Pharmacol; 2021; 12():781623. PubMed ID: 35082669
[TBL] [Abstract][Full Text] [Related]
37. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
38. The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo.
Xu CX; Li Y; Yue P; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
PLoS One; 2011; 6(6):e20899. PubMed ID: 21695126
[TBL] [Abstract][Full Text] [Related]
39. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
40. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]